Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 23, 2025

Merck KGaA says high asset prices call for prudent M&A approach

DAVOS, Switzerland (Reuters) - The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

"We need to stay prudent and patient because our business is returning to growth organically. We are not in a rush," CEO Belen Garijo told Reuters in an interview on the sidelines of the World Economic Forum's annual meeting in Davos, Switzerland.

Merck is focused in particular on strengthening its Life Science unit, a maker of lab gear and supplies, but asset prices when measured as a multiple of earnings are high, she added.

(Reporting by Divya Chowdhury in Davos; Writing by Ludwig Burger; Editing by Friederike Heine)

Recommended for you

  • Micheál Martin returns as Irish prime minister amid Trump threat

  • Poland's PGE in preliminary agreement to buy assets from ZE PAK

  • Volkswagen to make added investments in United States, CFO says at Davos